Receive the Company’s Press releases

Invalid Input
Invalid Input
Invalid Input
Invalid Input
Invalid Input
Invalid Input

Press Releases

2019 November 25 07:00 ASIT biotech gp-ASIT+TM Phase III trial in grass pollen allergy did not meet the primary endpoint pdf
2019 November 15 10:30 Declaration of dissociation of a member of the Board of Directors at the General Assembly pdf
2019 October 17 07:00 ASIT biotech mode of action study of gp-ASIT+™ for grass pollen allergy published in The Journal of Allergy and Clinical Immunology (JACI) pdf
2019 October 07 07:00 ASIT biotech receives GMP certification for its manufacturing site in Liège, Belgium pdf
2019 September 26 07:00 ASIT biotech firmly on course for readout of Phase III clinical study in grass pollen allergy pdf
2019 September 18 12:24 ASIT biotech presents its 2019 half year results and provides further update on its clinical programs until end-2019 pdf
2019 September 10 12:21 ASIT biotech conference calendar H2 2019 pdf
2019 September 05 12:19 Successful pollen season confirms ASIT biotech on track for Phase III results of gp-ASIT+TM in December 2019 pdf
2019 July 22 17:45 ASIT biotech Raises EUR 9.225 Million in a Private Placement of Convertible Notes pdf
2019 July 18 07:00 ASIT biotech Announces the Launch of a Private Placement of Convertible Notes pdf
2019 July 01 07:00 ASIT Biotech continues its transformation from research to late stage clinical development pdf
2019 May 27 07:00 ASIT Biotech to Participate in Multiple Upcoming Industry Events pdf
2019 May 14 18:00 ASIT biotech: publishes the documents relating to the Ordinary General Shareholders’ Meeting on 13 June 2019 pdf
2019 May 13 17:45 ASIT biotech announces the publication of its 2018 full-year financial report pdf
2019 May 02 07:00 ASIT biotech announces the achievement of new clinical and corporate development milestones pdf
2019 April 26 18:00 ASIT biotech to publish its annual financial report on May 13, 2019 pdf
2019 April 02 07:00 ASIT biotech provides clinical update and publishes its 2018 full-year results pdf
2019 March 29 07:00 ASIT biotech’s Scientific Advisory Boards (SAB) provide positive recommendations on the clinical development of gp-ASIT+™ pdf
2019 March 05 17:45 ASIT biotech reveals the mode of action of its lead immunotherapy product for Allergic Rhinitis, gp-ASIT+™, in The Journal of Allergy and Clinical Immunology (JACI) pdf
2019 February 25 07:00 ASIT biotech is confident in the execution of its key priorities for 2019 pdf
2019 February 19 07:00 2019 Financial Calendar pdf
2019 January 31 07:00 First patient treated with gp-ASIT+™ within the framework of the confirmatory Phase III study in grass pollen rhinitis pdf
2019 January 16 07:00 Ongoing restructuring of ASIT biotech organization to maximize the success of gp-ASIT+™ in grass pollen rhinitis pdf
2018 December 19 07:00 Summary of the Shareholders’ Meeting of December 17, 2018 and the Board Meeting of December 18, 2018 pdf
2018 December 17 07:00 ASIT biotech reaches another key milestone by finalizing the industrialization process for the manufacture of clinical batches of its hdm-ASIT+™ product candidate for house dust mite allergy pdf
2018 November 28 17:45 Kepler Cheuvreux publishes an initiation of coverage report on ASIT biotech pdf
2018 November 26 07:00 ASIT biotech has installed and qualified a pilot unit to produce clinical batches for the Phase I/II studies in house dust mite and peanut allergies pdf
2018 November 19 07:00 ASIT biotech launches its confirmatory Phase III clinical study with gp-ASIT+™ in grass pollen rhinitis prevention pdf
2018 November 12 18:00 ASIT biotech reaches a key milestone by finalizing the industrialization process for the manufacture of clinical batches of its pnt-ASIT+™ product candidate pdf
2018 November 05 08:00 ASIT biotech initiates the search for a strategic commercial partner for the future marketing of gp-ASIT+™ pdf
2018 October 08 17:45 ASIT biotech receives the Best Biopharmaceutical Corporate Governance Belgium 2018 Award pdf
2018 September 19 07:00 ASIT biotech presents its 2018 half-year results and provides an update on its clinical programs until end-2019 pdf
2018 September 05 17:45 Bryan, Garnier & Co. publishes an initiation of coverage report on ASIT biotech pdf
2018 July 11 16:15 ASIT Biotech Raises €12 Million of Commitments in a Convertible Bond Private Placement that was Heavily Oversubscribed pdf
2018 July 10 18:45 ASIT biotech Announces Private Placement of Convertible Bonds pdf
2018 June 25 07:00 ASIT biotech selects a new product candidate hdm-ASIT+™ for the high-potential market for treating house dust mite allergy pdf
2018 June 11 07:00 ASIT biotech selects a first ASIT+™ product candidate for the development of a treatment for peanut allergy pdf
2018 May 30 17:45 The equity research company Edison publishes an initiation of coverage report on ASIT biotech pdf
2018 May 16 17:45 Availability of the documents relating to the Ordinary General Meeting on 14 June 2018 pdf
2018 May 02 07:30 ASIT biotech identifies an original mechanism of action for gp-ASIT+™ that is the basis for a new method for the in vitro selection of future ASIT+™ products for allergy immunotherapy pdf
2018 April 18 07:00 ASIT biotech announces the publication of its 2017 annual financial report pdf
2018 March 12 07:00 The quality of the results obtained in the phase III clinical study with gp-ASIT+™ confirmed by the publication in the prestigious scientific journal ALLERGY pdf
2018 February 23 18:30 ASIT biotech successfully completes the second tranche of its capital increase, reaching a total amount raised of €13.9 million pdf
2018 February 12 07:00 ASIT biotech 2017 Annual Results: ongoing ASIT+™ products development in respiratory and food allergies pdf
2018 January 25 18:30 ASIT biotech successfully completes the first tranche of its capital increase and raises €9.4 million pdf
2018 January 11 18:00 ASIT biotech is publishing a new article on the clinical result of gp-ASIT+™ in the prestigious science journal ALLERGY pdf
2017 December 14 18:15 ASIT biotech reviews the efficacy results of gp-ASIT+™ observed during the phase III trial completed in 2016 pdf
2017 December 08 07:00 ASIT biotech Shareholders Meeting has approved the structure of the next financing round pdf
2017 December 06 07:00 ASIT biotech significantly moves forward in the preparation of the clinical development plan of gp-ASIT+™ in the US pdf
2017 December 01 17:45 2018 Financial Calendar pdf
2017 November 30 19:00 Newly published Phase IIb clinical results with gp-ASIT+™ in the ALLERGY journal highlight outstanding clinical and remarkable immunological effects pdf
2017 November 23 07:00 European Patent Office grants to ASIT biotech a second patent related to the active ingredients used in the ASIT+™ allergy immunotherapy product candidates pdf
2017 November 07 14:30 ASIT biotech: publishes the documents relating to the Extraordinary General Shareholders’ Meeting on 7 December 2017 pdf
2017 November 07 07:00 In line with the business plan presented at the IPO, ASIT biotech prepares an additional fund raising to further develop its products pdf
2017 October 24 17:45 ASIT biotech publishes the results of the hdm-ASIT+™ Phase I/II follow-up study in house dust mite rhinitis pdf
2017 October 17 18:30 ASIT biotech announces the grant of a European patent on the active ingredients used in the ASIT+™ allergy immunotherapy product candidates pdf
2017 October 12 17:45 ASIT biotech announces the publication of its first clinical data with gp-ASIT+™ in the Journal of Allergy and Clinical Immunology pdf
2017 September 14 08:30 ASIT biotech announces the publication of its 2017 half-year financial report pdf
2017 September 14 08:00 ASIT biotech presents its 2017 half-year results and provides update on its clinical programs pdf
2017 September 07 18:00 ASIT biotech to publish its half-year 2017 results on Thursday 14 September 2017 pdf
2017 August 16 17:45 ASIT biotech announces the approval by the regulatory authorities of a follow-up study of the Phase I/IIa clinical trial with its hdm-ASIT+™ product candidate for house dust mite rhinitis pdf
2017 July 03 07:01 ASIT biotech presented the immunogenicity data of the gp-ASIT+™ phase III clinical study for the treatment of grass pollen rhinitis at EAACI 2017 pdf
2017 July 03 07:00 Presentation of Dr. Shamji at EAACI 2017 pdf
2017 June 19 07:00 ASIT biotech discloses comments from the Paul Ehrlich Institute and presents detailed results on the phase III clinical study of gp-ASIT+™ at EAACI 2017 pdf
2017 May 30 18:45 ASIT biotech to disclose the detailed results of its phase III clinical study with gp-ASIT+™ at EAACI 2017 pdf
2017 April 25 17:45 ASIT biotech announces the publication of its 2016 annual financial report pdf
2017 April 20 19:30 ASIT biotech to publish its annual financial report on Tuesday, April 25, 2017 pdf
2017 April 11 17:45 ASIT biotech presents its 2016 annual results and recent updates in clinical developments pdf
2017 April 04 18:00 ASIT biotech announces that it has achieved the primary endpoint of the Phase I/IIa clinical trial with its hdm-ASIT+™ product candidate for house dust mite rhinitis pdf
2017 March 20 07:30 ASIT biotech announces the appointment of Gerd Zettlmeissl as the Company’s new Chairman of the Board pdf
2017 February 28 19:00 ASIT biotech reports positive results in its Phase III clinical trial with gp-ASIT+™ for grass pollen induced allergic rhinitis pdf
2017 February 27 08:30 ASIT biotech will publish the results of the phase 3 clinical trial with its gp-ASIT+™ product candidate for treating grass pollen rhinitis on 28 February, 2017 pdf
2017 January 24 08:30 ASIT biotech announces Last Patient Last Visit in the phase IIa clinical study with its hdm-ASIT+™ product candidate for treating house dust mite rhinitis pdf
2017 January 12 08:30 ASIT biotech receives 6 million euros in funding from the Walloon government for the development of new drug candidates to treat food allergies pdf
2017 January 03 18:00 2017 Financial Calendar pdf
2016 December 05 18:00 ASIT+™ technology's benefits in treating grass pollen rhinitis presented during a scientific session at Medical Research Council & Asthma UK Centre in LondonSIT Biotech has completed the recruitment of its phase IIa clinical study with hdm-ASIT+™ in house pdf
2016 November 30 18:00 ASIT Biotech has completed the recruitment of its phase IIa clinical study with hdm-ASIT+™ in house dust mite rhinitis pdf
2016 November 14 18:00 ASIT biotech takes important steps in US clinical development of gp-ASIT+™, its lead drug candidate for grass pollen rhinitis pdf
2016 October 05 18:00 ASIT biotech announces the last patient last visit in the Phase III clinical study with its first product candidate gp-ASIT+™ pdf
2016 September 23 18:00 ASIT biotech presents its results for the first half of 2016 and its recent clinical breakthroughs pdf
2016 September 22 18:00 ASIT biotech announces the initiation of a phase 2a clinical study of its product candidate hdm-ASIT+TM for house dust mite rhinitis pdf
2016 July 26 18:00 ASIT biotech appoints Prof. Mohamed Shamji as Scientific Advisor for the discovery of new drug candidates and for pre-clinical activities pdf
2016 June 21 18:00 ASIT biotech presents its recent corporate developments pdf
2016 June 14 18:00 End of the stabilization period, non-exercise of the over-allotment option pdf
2016 June 13 18:00 Setting up of a liquidity contract with Bank Degroof Petercam pdf
2016 May 10 18:00 ASIT biotech raises EUR 23.5 million in successful initial public offering pdf
2016 April 28 08:30 ASIT biotech launches its IPO on Euronext Brussels and Euronext Paris pdf
2016 April 14 08:30 ASIT biotech announces its intention to launch an Initial Public Offering and to list its shares on Euronext Brussels and Euronext Paris pdf
2015 August 17 18:00 A major milestone for ASIT biotech pdf
2015 June 11 18:00 EAACI 2015 Congress in Barcelona: clinical result presentation pdf
2014 December 01 18:00 Positive results of Phase IIb with gp-ASIT+™, allowing for fast launch of Phase III pdf
2014 May 28 08:30 EAACI 2014 Congress in Copenhagen: clinical result presentation pdf